ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin ... - Medpage Today

The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B-cell lymphoma.

Janssen and Legend Biotech announced early termination of a phase III trial after an interim analysis showed that ciltacabtagene autoleucel (cilta-cel, Carvykti) met the primary endpoint of improved progression-free survival in lenalidomide (Revlimid)-refractory multiple myeloma versus two active control regimens.

Where does your state fall in the American Lung Association's annual list of tobacco-control efforts?

In studies involving artificial human skin, scientists prevented development of invasive skin cancer in a laboratory model. (University of Copenhagen, Science Signaling)

Combining immunotherapy and targeted therapy led to durable responses in a difficult-to-treat form of colon cancer. (Mass General Cancer Center, Nature Medicine)

Takeda announced acquisition of a worldwide license (excluding China) to market and distribute the VEGF receptor inhibitor fruquintinib.

Merck announced termination for futility of a phase III trial after an interim analysis showed the combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) was unlikely to improve survival in metastatic hormone-sensitive prostate cancer.

At the same time, Merck said a phase III trial of pembrolizumab plus chemotherapy improved survival in advanced biliary tract cancer as compared with chemotherapy alone.

Magenta Therapeutics voluntarily paused an early-stage trial of the antibody-drug conjugate MGTA-117 in relapsed/refractory acute myeloid leukemia or myelodysplastic syndromes to investigate the drug's safety following the death of a patient in the trial.

An early-phase trial of the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in chronic lymphocytic leukemia/small lymphocytic lymphoma met the primary endpoint of objective response, Bristol Myers Squibb announced.

• 

  Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Adblock test (Why?)